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Abstract: Pancreatic ductal adenocarcinoma (PDAC) is amongst the most fatal malignancies and
its development is highly associated with inflammatory processes such as chronic pancreatitis (CP).
Since the succinate dehydrogenase subunit B (SDHB) is regarded as tumor suppressor that is lost
during cancer development, this study investigated the impact of M1-macrophages as part of the
inflammatory microenvironment on the expression as well as function of SDHB in benign and
premalignant pancreatic ductal epithelial cells (PDECs). Immunohistochemical analyses on pancreatic
tissue sections from CP patients and control individuals revealed a stronger SDHB expression in
ducts of CP tissues being associated with a greater abundance of macrophages compared to ducts
in control tissues. Accordingly, indirect co-culture with M1-macrophages led to clearly elevated
SDHB expression and SDH activity in benign H6c7-pBp and premalignant H6c7-kras PDECs. While
siRNA-mediated SDHB knockdown in these cells did not affect glucose and lactate uptake after
co-culture, SDHB knockdown significantly promoted PDEC growth which was associated with
increased proliferation and decreased effector caspase activity particularly in co-cultured PDECs.
Overall, these data indicate that SDHB expression and SDH activity are increased in PDECs when
exposed to pro-inflammatory macrophages as a counterregulatory mechanism to prevent excessive
PDEC growth triggered by the inflammatory environment.
Keywords: pancreatic cancer; SDHB; macrophages; inflammatory stroma; chronic pancreatitis
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1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the 4th most frequent cause of cancer-related
deaths in Western countries [1,2]. The overall 5-year-survival rate is still below 10% which is mainly
due to the lack of reliable tests for early detection of this tumor. Therefore, PDAC is commonly
diagnosed in an advanced incurable stage [3,4]. Besides age and life style factors such as smoking,
a long-standing chronic pancreatitis (CP) has been shown to be an important risk factor for PDAC
development [5–7]. Different precursor lesions have been identified which can give rise to PDAC with
pancreatic intraepithelial neoplasia (PanIN) being the most frequent and best characterized precursor
lesions [3,4]. PanINs are also abundant in CP and like CP PDAC is characterized by a profound
inflammatory stroma accounting for up to 90% of the tumor mass. This so-called desmoplastic
reaction already starts to evolve at the stage of precursor lesions or CP [5,8–10]. In addition to a large
non-cellular compartment, CP and PDAC stroma comprise various non-neoplastic cell populations
including myofibroblasts, T cells and macrophages [8–10]. Among these, macrophages constitute one
of the earliest and major immune cell populations in both CP and PDAC stroma [8–10]. Functionally,
macrophages are roughly divided into classically activated or pro-inflammatory M1-macrophages
and alternatively activated or anti-inflammatory M2-macrophages [11]. The M1-polarization can
be induced by Granulocyte/Macrophage-Colony Stimulating Factor (GM-CSF) or bacterial products
like lipopolysaccharides (LPS) and is characterized by an increased secretion of pro-inflammatory
cytokines like IL-1β, IL-6 and TNF-α [12]. The fact that M1-macrophages are more abundant in
CP than PDAC stroma is constituent with the role of this phenotype in initiation, promotion and
maintenance of inflammatory responses [13,14]. Based on their gene expression profile and secretome,
(tumor-associated) macrophages are assumed to essentially contribute to malignant transformation as
well as tumor growth, apoptosis resistance and cell invasion [15].
Besides the central role of inflammatory cells such as macrophages in PDAC initiation and
progression, reprogramming of the cellular metabolism in pancreatic ductal epithelial cells (PDECs)
might also contribute to increased proliferative activity and resistance towards apoptotic stimuli
in PDECs, thereby facilitating malignant progression [16]. Indeed, recent studies indicate a high
addiction of PDAC progression to metabolic alterations and tumor metabolism is assumed to be
its “Achilles Heel” [16,17]. As a hallmark of cancer, metabolic reprogramming has been shown to
essentially promote tumor development [18,19]. For the first time, Otto Warburg described that
tumor cells show an altered metabolism that is characterized by high glycolytic activity and lowered
oxidative phosphorylation [20]. In this context, tumor cells may fuel glycolysis-associated pathways to
metabolize glucose and generate building blocks for enhanced DNA synthesis and redox homeostasis,
e.g., the pentose phosphate pathway (PPP), or adapt their metabolism for utilization of alternative
carbon sources like glutamine [21,22]. Importantly, the metabolic status of tumors and putatively also
their precursor cells seems to be highly dynamic and depends on microenvironmental conditions (e.g.,
stromal composition due to inflammatory processes) [23–28]. Succinate dehydrogenase (SDH) is an
important mitochondrial enzyme involved in the tricarboxylic acid (TCA) cycle as well as the electron
transport chain. The SDH subunit B (SDHB) being one of the four subunits of SDH and the essential
one for electron transport is regarded as tumor suppressor because its mutational inactivation or its
decreased expression has been observed in several tumor entities [29,30]. In certain tumor entities such
as pheochromocytomas genetic predisposition together with SDHB mutations have been described
to lead to functional loss of SDHB [31,32]. Thus, regulation of SDHB expression might be a critical
determinant in controlling cell growth and behavior of PDECs in premalignant pancreatic lesions
thereby counteracting accelerated cell proliferation and malignant transformation.
Addressing this issue, the present study investigated the impact of an M1-macrophage shaped
inflammatory microenvironment on the expression of SDHB and SDH activity in benign and premalignant
PDECs in order to get a better understanding of the role of SDHB in inflammation-associated
pancreatic carcinogenesis.
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2. Results
2.1. Elevated SDHB Expression in Ducts of Chronically Inflamed Pancreata
Since CP represents one major risk factor for PDAC development [5–7], it was investigated whether
a chronically inflamed microenvironment alters gene expression of SDHB, a metabolic key protein
and described tumor suppressor, in pancreatic ducts. Thus, the expression of SDHB was examined in
pancreatic tissues of CP patients and compared to pancreatic tissue sections from individuals who
did not die from any pancreatic disease (control tissue). As shown in Figure 1A+B, strong SDHB
expression was detectable in ducts exhibiting considerable morphological alterations associated with
PanINs in inflamed areas of tissues from CP patients.
Figure 1. Elevated SDHB expression in pancreatic ducts of CP patients compared to ducts of
healthy individuals. Representative images of immunohistochemical stainings of (A+B) succinate
dehydrogenase subunit B (SDHB) and (C) CD68 in tissue sections from two CP patients (CP) and two
individuals who did not die due to a pancreatic disease (control). Arrow heads indicate CD68+ cells in
control samples. Scale bar = 150 µm. (B) Quantification of immunohistochemical analyses of SDHB
staining in pancreatic ducts of CP patients (n = 10) and control individuals (n = 22). Pie charts present
the proportion of ducts showing weak, intermediate and strong SDHB staining in 523 ducts of CP
tissues and 739 ducts of control tissues.
In contrast, ducts showing a physiological morphology and being located in an uninflamed
microenvironment also exhibited SDHB expression but much less pronounced than under CP conditions
(Figure 1A+B). Thus, in CP tissues 21.2% of ducts were characterized by strong SDHB expression, while
only 3.3% in control tissues (Figure 1B). Furthermore, in 7/10 CP cases an increased SDHB expression
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could be correlated with an elevated presence of CD68+ macrophages (Figure 1C). Thus, as determined
by staining of CD68 in a former study [14], macrophages were highly abundant in the stroma next to
epithelial ducts while only rarely found in healthy control tissues (Figure 1B indicated by the arrow
heads). Overall, these data suggest that SDHB expression is elevated in pancreatic ductal epithelium
when exposed to an inflammatory microenvironment enriched with macrophages.
2.2. Co-culture with M1-macrophages Increases SDHB Expression in H6c7-pBp and H6c7-kras Cells
In order to investigate if paracrine interactions with pro-inflammatory macrophages being
highly abundant in the stroma of CP tissues [14] lead to an increased expression of SDHB and other
metabolism-associated enzymes in benign and premalignant PDECs, an indirect co-culture system
was applied using benign H6c7-pBp and premalignant H6c7-kras cells and the expression of SDHB
was analyzed. In line with the findings from staining of CP tissues, SDHB expression was clearly
enhanced in H6c7-pBp and H6c7-kras cells after co-culture with M1-macrophages (M1-macrophages)
as demonstrated by western blotting (Figure 2A) and immunofluorescence staining (Figure 2B).
Interestingly, glucose-6-phosphate dehydrogenase (G6PD), the rate limiting enzyme of the PPP
that catalyzes the oxidation of glucose-6-phosphate into 6-phosphoglucono-δ-lactone generating
NADPH+H+, was concomitantly expressed at lower levels in PDECs from co-culture compared to
those from mono-cultures (Figure 2A+B).
Figure 2. Cont.
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Figure 2. Elevated SDHB expression and SDH activity in H6c7-pBp and H6c7-kras cells after
exposure to pro-inflammatory macrophages. PDECs were mono- or indirectly co-cultured with human
M1-macrophages (coM1) for five days. (A) Representative western blots of SDHB and G6PD in
whole-cell lysates from differently cultured H6c7-pBp and H6c7-kras cells. HSP90 was detected as
loading control. Values from densitometric analysis are noted below the bands. Values of mono-cultured
cells were set as 1. In brackets, normalized values relative to respective Hsp90 values are shown.
Representative results from three independent experiments are shown. G6PD: glucose-6-phosphate
dehydrogenase; SDHB: succinate dehydrogenase subunit B. (B) Representative fluorescence microscopic
images of SDHB and G6PD staining in differentially cultured H6c7-pBp and H6c7-kras cells. Nuclear
staining was performed with Hoechst. Scale bar = 100 µm. Quantification of SDHB and G6PD staining
in H6c7-pBp and H6c7-kras cells (right). Bar chart presents mean values +/- SEM of 3 independent
experiments. (C) SDH activity of mono- and co-cultured H6c7-pBp and H6c7-kras cells. Data are
expressed in nmol/min SDH activity normalized to protein content (in mg) of the sample. Data represent
mean +/- SEM of 3-4 independent experiments. * p < 0.05.
In contrast, the expression of other metabolic enzymes (transketolase, transaldolase,
glycerinaldehyde-3-phosphate dehydrogenase, lactate dehydrogenase A/B) and metabolite transporters
(monocarboxylate transporter 1/2) in H6c7-pBp and H6c7-kras cells was not affected by co-culture
conditions (data not shown). In line with the elevated SDHB expression, both PDEC lines exhibited an
elevated SDH activity after co-culture with M1-macrophages, with an effect being more pronounced
in H6c7-pBp than in H6c7-kras cells (Figure 2C). Accordingly, elevated SDHB expression and SDH
activity seems to be associated with an enhanced oxidative phenotype of the cells (Appendix A,
Figure A1). In summary, these data support the view that paracrine interaction with pro-inflammatory
macrophages increases the expression of SDHB as well as SDH activity and simultaneously decreases
the expression of G6PD in PDECs.
2.3. siRNA Mediated Downregulation of SDHB Expression Diminishes SDH Activity in H6c7-pBp and
H6c7-kras cells after Mono- and Co-culture with M1-macrophages
In order to investigate the role of SDHB in PDECs under inflammatory conditions, SDHB
expression was silenced by transient siRNA-mediated knockdown. Analysis of SDHB expression
after siRNA treatment revealed a clearly reduced SDHB expression in both H6c7-pBp and H6c7-kras
cells under mono- and co-culture conditions as demonstrated by western blotting (Figure 3A) and
immunofluorescence staining (Figure 3B+C). Notably, G6PD expression was markedly elevated in siSDHB
transfected PDECs in comparison to siCtrl treated cells (Figure 3B) but none of the other examined enzymes
(transketolase, transaldolase, glycerinaldehyde-3-phosphate dehydrogenase, lactate dehydrogenase A/B)
or transporters (monocarboxylate transporter 1/2) (data not shown). Furthermore, SDHB knockdown also
reduced SDH activity except in co-cultured H6c7-pBp cells (Figure 3D). In summary, these data show that
siRNA mediated SDHB silencing specifically reduces SDHB expression and activity.
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Figure 3. SiRNA mediated downregulation of SDHB expression diminishes SDH activity in H6c7-pBp
and H6c7-kras cells after mono- and co-culture with M1-macrophages. H6c7-pBp and H6c7-kras cells
were transfected with either control siRNA (siCtrl) or SDHB specific siRNA (siSDHB) followed by either
mono- or indirect co-culture with human M1-macrophages (coM1) for five days. (A) Representative
western blots of SDHB and G6PD in whole-cell lysates of differentially cultured PDECs. HSP90 was
detected as loading control. Values from densitometric analysis are noted below the bands. Values of
mono-cultured siCtrl treated cells were set as 1. In brackets, normalized values relative to respective
Hsp90 values are shown. Representative results from 3 independent experiments are shown. G6PD:
glucose-6-phosphate dehydrogenase; SDHB: succinate dehydrogenase subunit B. (B) Representative
fluorescence microscopic images of SDHB and G6PD staining in H6c7-pBp and H6c7-kras cells after
indicated treatment conditions. Nuclear staining was performed with Hoechst. Scale bar = 100 µm.
(C) Quantification of SDHB staining in H6c7-pBp and H6c7-kras cells. Data were normalized to
mono-cultured siCtrl transfected cells and are presented as mean +/- SEM of 3 independent experiments.
(D) SDH activity of H6c7-pBp and H6c7-kras cells after indicated treatment conditions expressed as
n-fold SDH activity of mono-cultured siCtrl treated cells. Data are represented as mean +/- SEM of 4
independent experiments. *p < 0.05.
2.4. Impact of Paracrine Interaction with M1-macrophages and SDHB Knockdown on Uptake of Glucose and
Lactate in H6c7-pBp and H6c7-kras Cells
An elevated uptake of glucose might be indicative for an increased metabolic flux into anabolic
pathways that foster cell proliferation, while a reduced uptake might indicate a metabolic switch
towards utilization of other carbon sources and presumably a less energy consuming state—e.g.,
quiescence. Thus, it was next investigated whether glucose uptake is impacted by M1-macrophages
and if so, whether this is dependent on elevated SDHB expression. As shown in Figure 4A+B 2-NBDG
uptake assay revealed that mono-cultured H6c7-kras cells exhibited a significantly lower glucose uptake
compared to H6c7-pBp cells (Figure 4A) and that the presence of M1-macrophages led to a reduced
glucose uptake in both PDEC lines compared to mono-culture. In line with the more pronounced
effects of the co-culture on SDHB expression and SDH activity, glucose uptake was more reduced
in H6c7-pBp cells than in H6c7-kras cells (Figure 4B). While under mono-culture, siRNA-mediated
knockdown of SDHB also reduced glucose uptake compared to control transfected cells, no further
reduction was observed after SDHB knockdown in the PDECs when exposed to M1-macrophages
(Figure 4B). Beside glucose, lactate is an important alternative energy source, particularly used by
tumor cells [33]. Hence, lactate uptake in mono- and co-cultured H6c7-pBp and H6c7-kras cells was
determined. Similar to the findings for glucose uptake, lactate was also taken up less by mono-cultured
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H6c7-kras cells compared to H6c7-pBp cells (Figure 4C) and both PDEC lines exhibited a reduced
lactate uptake after co-culture with M1-macrophages compared to mono-cultured cells (Figure 4D).
Noteworthy, this effect could not be reversed by knockdown of SDHB. Overall, these findings indicate
that PDECs exhibit a reduced uptake of glucose and lactate in the presence of M1-macrophages. Since
the macrophage mediated effect on glucose and lactate uptake was not influenced by knockdown of
SDHB, the observed increase in SDHB expression and SDH activity under these conditions might be
rather the consequence than the cause of the altered glucose/lactate uptake in PDECs.
Figure 4. Glucose and lactate uptake in H6c7-pBp and H6c7-kras cells is reduced in the presence of
M1-macrophages but not reversed by SDHB knockdown under co-culture conditions. (A+B) Determination
of 2-NBDG uptake and (C+D) 14C lactate uptake in H6c7-pBp or H6c7-kras cells transfected with either
control siRNA (siCtrl) or SDHB specific siRNA (siSDHB) followed by mono- or indirect co-culture with
human M1-macrophages (coM1) for five days. Data represent mean +/- SEM of 7 independent experiments.
Data are expressed as (A) glucose and (C) 14C-lactate uptake or as n-fold (B) glucose uptake and (D) lactate
uptake normalized to respective mono-cultured siCtrl transfected cells. * p < 0.05.
2.5. Elevated Cell Growth of H6c7-pBp and H6c7-kras Cells in the Presence of M1-macrophages is Further
Enhanced by Downregulation of SDHB Expression
Since an enhanced and uncontrolled proliferative activity is a characteristic property gained
during malignant transformation and macrophages have been described to promote epithelial cell
proliferation [24], it was investigated if M1-macrophages affect cell growth of H6c7-pBp and H6c7-kras
cells and whether this relates to the elevated SDHB expression. Vital cell countings revealed slightly
increased cell numbers of PDECs co-cultured with M1-macrophages in comparison to mono-cultured
cells, with effects being again more pronounced in H6c7-pBp cells than in H6c7-kras cells (Figure 5A).
In line with these findings, the proportion of Ki67+ cells was elevated (Figure 5B). Moreover, caspase-3/7
activity indicative for apoptotic cells was slightly increased (Figure 5C) in H6c7-pBp cells and slightly
decreased in H6c7-kras cells under co-culture conditions. Importantly, siRNA-mediated silencing of
SDHB expression clearly elevated the number of vital as well as the proportion of proliferating cells
and reduced caspase-3/7 activity of both PDEC lines under either culture condition. Notably, this effect
was more pronounced in PDECs from co-culture with M1-macrophages (Figure 5A+B). Hence, highest
vital cell numbers were counted in co-cultured H6c7-pBp and H6c7-kras cells when SDHB expression
was silenced (both 2.16-fold). These data suggest that elevated expression of SDHB under co-culture
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conditions is a counterregulatory mechanism to control excessive cell growth of PDECs in the presence
of pro-inflammatory macrophages.
Figure 5. Elevated cell growth of H6c7-pBp and H6c7-kras cells in the presence of M1-macrophages
is further enhanced by downregulation of SDHB expression. H6c7-pBp and H6c7-kras cells were
transfected with either control siRNA (siCtrl) or SDHB specific siRNA (siSDHB) followed by either
mono- or indirect co-culture with human M1-macrophages (coM1) for five days. (A) Determination of
vital cell numbers, (B) proportion of Ki-67+ cells and (C) caspase-3/7 activity in differentially cultured
cells. Data are expressed as n-fold change normalized to respective mono-cultured siCtrl transfected
cells. Data represent mean +/- SEM of 3 independent experiments. * p < 0.05.
3. Discussion
CP, one of the main risk factors for PDAC containing precursor lesions such PanINs, as well
as PDAC are characterized by a high abundance of macrophages [14,34]. It has been shown that
macrophages promote malignancy associated alterations already in PDECs paving the way for PDAC
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development [7,10,13]. SDHB belongs to the SDH complex in mitochondria and has been described
as a tumor suppressor [35]. Accordingly, a loss of SDHB function can be observed in many tumor
entities and during PDAC progression a reduction in SDHB expression has been described, too [36–39].
Our immunohistochemical analyses of CP tissues revealed a higher SDHB expression in PanINs
compared to ducts of unaffected pancreata. Interestingly, a high abundance of macrophages close
to PanINs showing increased SDHB expression could be detected in the majority of CP tissues
while normal ducts with lower SDHB expression were located in an unobtrusive microenvironment
suggesting a link between pro-inflammatory macrophages and elevated SDHB expression in PanINs.
In line with these in situ findings, indirect co-culture with pro-inflammatory macrophages, mimicking
the paracrine interplay of macrophages and PDECs in CP tissues, led to an elevated SDHB expression
and SDH activity on the one hand and a reduced expression of G6PD on the other hand in both
H6c7-pBp and H6c7-kras cells. With regard to these findings, an elevated SDHB expression and
SDH activity (along with a reduced expression of G6PD) may relate to a metabolic switch of the
cells which is associated with enhanced OXPHOS activity contrasting the tumor associated Warburg
phenotype that is characterized by an increased glucose uptake and elevated glycolysis under aerobic
conditions [21,40,41]. In line with this assumption, glucose uptake was rather reduced in both PDEC
lines after co-culture with M1-macrophages and similar observations were also made with respect to the
uptake of lactate, an alternative carbon source especially for tumor cells [23,42–44]. Furthermore, first
Seahorse analyses indicate that co-cultured PDECs indeed exhibit an enhanced oxygen consumption
(Appendix A, Figure A1). Overall, these results suggest that PDECs adapt a more oxidative than
glycolytic phenotype due to paracrine interaction with M1- macrophages. Ongoing studies have to
reveal in more detail how this relates to a metabolic shift in the cells.
In order to examine whether elevated SDHB expression might be the cause or the consequence
of an altered metabolism in PDECs in the presence of macrophages, SDHB expression was silenced
by siRNA transfection. However, knockdown of SDHB did not reverse the co-culture mediated
reduction of glucose and lactate uptake but it independently led to a diminished uptake of the
two metabolites. Interestingly, SDHB silencing significantly increased cell growth due to elevated
proliferation and reduced effector caspase activity in both PDEC lines under co-culture conditions.
Hence, G6PD expression was downregulated in PDECs in the presence of M1-macrophages but
markedly upregulated when SDHB expression was silenced in PDECs. Notably, an increased metabolic
flux into the PPP due to increased expression and activity of G6PD would provide more NADPH+H+
for anabolic processes as well as ribose for DNA synthesis and, thereby, provide the basis for the
enhanced proliferative activity of PDECs transfected with SDHB-targeting siRNA. Moreover, increased
NADPH levels may also provide redox equivalents for protecting the cells against reactive oxygen
species (ROS) [45]. In conclusion, our data indicate that PDECs adapt metabolic alterations under
inflammatory conditions. These adaptations are characterized by an increased SDHB and decreased
G6PD expression. On the functional level, SDHB levels affect SDH activity as well as the regulation
of cell proliferation and apoptosis induction and, by that, counteract M1-macrophages promoted
cell growth. In line with these findings, it has been shown in e.g., ovarian and colorectal cancer
cells that a lack of SDHB leads to HIF-1-dependent metabolic alterations towards a more glycolytic
phenotype [36,46] which is associated with induction of Epithelial-Mesenchymal-Transition (EMT)
and elevated proliferation [37,38,47].
Since in our study an indirect co-culture setting was used, the observed alterations in PDECs have to
be mediated in a paracrine fashion. Indeed, TNF-αwhich is highly secreted by M1-macrophages [48] has
been shown to induce the expression of anti-apoptotic genes such as Bcl-2 and c-FLIP genes via activation
of NF-κB, thereby leading to a protection from apoptosis induction and enhanced survival [49,50].
Moreover, TNF-α signaling is also known to block Y box binding protein 1 (YB-1)-mediated degradation
of SDHB mRNA and thereby leads to its enhanced expression [51,52] which might represent an
explanation for enhanced SDHB expression in PDECs in the presence of M1-macrophages.
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It has been shown that SDH dissociation into membrane bound SDHC/D and soluble SDHA/B in
response to pro-apoptotic stimuli amplifies apoptosis induction by transferring electrons to oxygen
and, thereby, generating harmful intracellular oxygen radicals. With regard to the tumor suppressor
function of SDHB its upregulation in PDECs due to co-culture with M1-macrophages might, thus, be
considered as a counterregulatory, tumor preventive mechanism in order to sensitize cells for apoptotic
stimuli and, thereby, impede excessive cell proliferation under pro-inflammatory conditions that favor
malignant transformation [35,53–55]. In this context, Guzy et al. provided evidence that SDHB does
not exert its tumor suppressive properties via bioenergetic regulation [35]. In line with this, it has been
shown that a lack or reduced expression of SDHB does not completely diminish succinate oxidizing
activity but the electron transport from the catalytic domain in SDH subunit A (SDHA) into the
electron transport chain. Thereby, electrons get stuck in SDHA leading to a Flavin adenine dinucleotide
(FAD) auto-oxidation and the generation of highly reactive superoxide. These ROS subsequently
activate HIF-1-mediated signaling which in turn enhances proliferation and vascularization [36,46].
Furthermore, ROS also promote genetic instability, thereby, paving the way for tumor promoting
mutations and malignant transformation [53].
4. Materials and Methods
4.1. Immunohistochemical Staining of SDHB in Human Pancreatic Tissues
Expression of SDHB in pancreatic ducts was detected in 3 µm-thick formalin-fixed
paraffin-embedded tissue sections of patients suffering from CP and patients without putatively
pathological pancreatic diseases. Tissue sections were kindly provided by B. Sipos (BAG für Pathologie
und Molekularpathologie Stuttgart, Germany). In case of the CP tissue sections, informed consent was
obtained and research was approved by the ethics committee of the University Hospital Tübingen
(reference number: 470/210BO1). Research on the pancreatic tissue sections of non-pathological origin
was authorized by the ethics committee of the Semmelweis University Budapest (reference number:
140-1/1996) and the need for an informed consent was waived. First, deparaffinization of tissue sections
was performed by incubating sections two-times in xylene for 10 min. Afterwards, samples were
rehydrated applying a descending alcohol series, simultaneously blocking endogenous peroxidases
by adding 1.5% (v/v) H2O2. Then, tissue sections were washed for 10 min with PBS before antigen
retrieval was performed by incubating the sections in a steamer for 20 min in pre-warmed antigen
retrieval buffer (citrate buffer, pH 6.0). After cooling down to room temperature (RT), tissues were
washed with PBS and unspecific binding-sites were blocked by incubation in PBS supplemented with
0.3% (v/v) Triton X-100 (PBS-T) and 4% (w/v) BSA for 1 h at RT. Then, anti-SDHB primary antibody
(clone EPR10880, Abcam, Cambridge, UK) diluted at 2.8 µg/mL in PBS-T supplemented with 1% (w/v)
BSA was applied and tissue sections were incubated in a wet chamber overnight at 4 ◦C. Detection
was carried out by EnVision + system-HRP labeled polymer anti-mouse or anti-rabbit, followed by
administration of AEC Substrate (both Dako Diagnostika, Hamburg, Germany). Nuclear staining
was performed with Mayer’s Haemalaun (AppliChem, Darmstadt, Germany). Respective isotype
controls were used to verify staining specificity. Semiquantitative evaluation of SDHB expression was
performed using the following scoring system: 1= weak staining intensity, 2= intermediate staining
intensity, 3= strong staining intensity. CD68 staining was already performed in a former study [14].
Images were taken with a Lionheart FX Automated microscope making use of the software Gen5 (both
from BioTek, Bad Friedrichshall, Germany).
4.2. Pancreatic Ductal Epithelial Cell Lines
The cell lines H6c7eR-pBp (harboring no PDAC-related mutations and being non-tumorigenic)
and H6c7eR-kras (harboring k-Ras G12V mutation and being partially tumorigenic), used as models for
benign and premalignant human PDECs present in CP tissues, respectively, were kindly provided by
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M.S. Tsao (Ontario Cancer Institute, Toronto, ON, Canada) and cultured as described previously [56–58].
All cell lines have recently been authenticated by STR-analysis.
4.3. Isolation and Generation of Pro-inflammatory M1-like Polarized Macrophages
Macrophages were generated from monocytes of healthy donors. Informed consent was received
from all donors. Monocytes were obtained from lymphocyte retaining systems from blood donations
at the Institute for Transfusion Medicine (Kiel, Germany). They were isolated by density gradient
centrifugation followed by counterflow centrifugation and differentiated into pro-inflammatory
M1-macrophages via stimulation with 50 ng/mL GM-CSF (240 U/mL) (BioLegend, Fell, Germany) for
seven days. The phenotype of M1-macrophages was routinely validated as described previously [13,28].
4.4. Indirect Co-cultures of PDECs and M1-macrophages
PDECs were seeded at 1.5 × 104 cells/well in 1 mL/well HPDE medium (50% (v/v) RPMI-1640
supplemented with 10% (v/v) fetal calf serum, 2 mM L-glutamine and 50% (v/v) keratinocyte serum-free
medium supplemented with 50 µg/mL bovine pituitary extract, 5 ng/mL Epidermal Growth Factor
and 4 µg/mL puromycin) into a 12-well plate. In parallel, M1-macrophages were seeded at 1.5 ×
105 cell/well in 1 mL/well RPMI-1640 medium supplemented with 10% fetal calf serum and 2 mM
L-glutamine into a 12-well plate transwell insert (0.4 µm pore size, Greiner, Frickenhausen, Germany).
After 24 hours, media were aspirated and replaced by RPMI-1640 medium supplemented with 10%
fetal calf serum and 2 mM L-glutamine. Finally, transwell inserts were placed into the wells containing
adherent PDECs. Co-cultures were carried out for five days until subsequent analyses were performed.
4.5. siRNA-mediated Knockdown of SDHB Expression
In order to perform siRNA-mediated knockdown of SDHB gene expression, PDECs were seeded
and cultured as described one day before harvesting M1-macrophages. Transfection of PDECs was
performed 24 h after seeding. For the transfection of cells in one 12-well, 100 µl Opti-MEM serum
reduced medium (Thermo Scientific, Schwerte, Germany) were mixed with 6 µL HiPerfect Transfection
Reagent (Qiagen, Hilden, Germany) and 1 µL of either 10 µM Control siRNA (sc-37007) or 10 µM
SDHB siRNA (sc-44088, both from Santa Cruz Biotechnology, Heidelberg, Germany) and incubated for
10 min at RT before being added to the cells. Eight hours later, medium was replaced by fresh medium.
4.6. Immunofluorescence Staining of SDHB and Ki67
Cells were seeded on cover slips (ø 18 mm; Thermo Scientific) and cultured as described.
Immunofluorescence staining was performed as previously described [39]. The following antibodies
were used: 1.7 µg/mL anti-SDHB (clone EPR10880, Abcam), 10 µg/mL anti-Ki67 clone B56;
BD Biosciences, Heidelberg, Germany) and 4 µg/mL of either anti-mouse IgG-Alexa Fluor 488
or anti-rabbit IgG-Alexa Fluor546 (Thermo Scientific). Nuclear staining was performed by incubation
in Hoechst 33258 (Sigma-Aldrich, St. Louis, MO, USA) diluted at 2 µg/mL in PBS for 1 hour at RT.
Afterwards, samples were mounted in FluorSave Reagent (Merck Millipore, Darmstadt, Germany) on
microscope slides. Staining specificity was verified by staining with isotype control antibodies (rabbit
IgG, clone SP137, Abcam). Images were taken with a Keyence BZ-9000 fluorescence microscope and
relative quantification was performed making use of the Hybrid Cell Count tool provided by BZ-9000
Image Analysis Application (both from Keyence, Neu-Isenburg, Germany).
4.7. Western Blotting
Whole cell lysates were prepared and electrophoresis as well as western blotting were performed as
described [59]. The following antibodies were used: anti-mouse IgG-HRP (#7076), anti-rabbit IgG-HRP
(#7074) (all from Cell Signaling, Frankfurt, Germany), anti-G6PD [H-160], anti-HSP90α/β [H-114] and
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anti-SDHB [FL-280] (all from Santa Cruz Biotechnology, Heidelberg, Germany). All antibodies were
diluted according to the manufacturer’s instructions.
4.8. Determination of vital cell numbers
Cells were detached with Trypsin-EDTA (PAA, Pasching, Germany) and counted using a
Neubauer counting chamber. In order to discriminate vital and dead cells a staining with trypan blue
(Sigma-Aldrich, Munich, Germany) was performed.
4.9. Measurement of Caspase-3/7 Activity
Caspase-3/7 activity was measured making use of the Caspase-Glo®assay (Promega, Mannheim,
Germany) according to the manufacturer’s instructions and as described [59]. Samples were measured
in duplicates and resulting values were normalized to the respective protein concentration.
4.10. Glucose Uptake Assay
After co-culture PDECs were washed with PBS. Subsequently, cells were incubated with
500 µL co-culture medium supplemented with 10 µM 2-(N-(7-nitrobenz-2-oxa-1.3-diazol-4-yl)
-amino)-2-deoxyglucose (2-NBDG, Thermo Scientific) at 37 ◦C for 30 min. Then, 2-NBDG supplemented
medium was withdrawn and cells were washed with PBS. Afterwards, cells were detached using
Trypsin/EDTA, transferred into 1.5 mL reaction tubes and 500 µL co-culture medium were added.
Then, cells were centrifuged for 5 min at 500·g and RT. Finally, cells were resuspended in 100 µL PBS,
transferred into FACS tubes and 2-NBDG uptake analysis was performed using a FACScalibur flow
cytometer (Beckton Dickinson, Heidelberg, Germany).
4.11. Lactate uptake assay
Lactate uptake by PDECs was examined using uniformly labeled 14C-lactate (Hartmann Analytics,
Braunschweig, Germany). After removal of the medium, cells were equilibrated in 250 µL 10 mM
Hepes/pH 7.50, 5 mM KCl, 100 mM NaCl, 1 mM MgCl2 (uptake buffer) containing 2 µCi (0.5 µM)
14C-L-lactate alone or together with 10 mM unlabeled lactate and cells were incubated for 2 h at 37 ◦C.
Afterwards, cells were washed thrice with ice-cold PBS and then lysed in 500 µL uptake-buffer with 2%
(w/v) SDS. Lysates were submitted to liquid-scintillation beta-counting (Packard TRI-CARB 2000TR
Liquid Scintillation Analyzer, GMI, Ramsey, MN, USA). In parallel, protein concentrations in lysates
from unlabeled cells were measured (DCTM-Assay) and used for normalization of beta-counting rates
(triplicate measurements). Values of control samples (incubation with non-labeled lactate), which
accounted for unspecific extracellular binding, were subtracted from corresponding sample values
which were incubated without additional non-labeled lactate.
4.12. Determination of Succinate Dehydrogenase Activity
For determination of SDH activity in PDECs, a colorimetric assay was used (adapted to [60]),
which is based on the reduction of artificial electron acceptor 2,6-dichlorphenol-indophenol (DCIP).
For this purpose, transwells with macrophages were removed after co-culture. PDECs were washed
with PBS, detached with Trypsin/EDTA for 10 min, transferred into a 1.5 mL reaction tube and
centrifuged at 500·g for 5 min at 4 ◦C. Afterwards, cells were resuspended in 100 µL isolation buffer
(210 mM mannitol, 70 mM sucrose, 10 mM 3-(N-morpholino)propanesulfonic acid, pH 7.2) and 5 µL of
the cell suspension were transferred into a 96-well plate in duplicates. Afterwards, 90 µL SDH assay
buffer (20 mM sodium succinate, 10 mM sodium azide, 25 mM disodium hydrogenphosphate, 25 mM
potassium dihydrogenphosphate, pH 7.4) were added and incubated for 5 min at RT to allow succinate
uptake and complex IV inhibition. Colorimetric reaction was started by adding 50 µM DCIP. In order to
determine molar enzymatic turnover, a DCIP standard was prepared with concentrations of 0, 12.5, 25,
and 50 µM DCIP in SDH Assay buffer. DCIP reduction was monitored by measuring absorbance at λ =
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600 nm every minute for 30 min, using an Infinite®M200 Pro microplate reader (TECAN, Crailsheim,
Germany). Resulting DCIP turnover was normalized to whole cell lysate protein concentration of
respective samples, generating values in the dimension nmol/min/mg protein. SDH-dependent DCIP
reduction was confirmed by performing dose-dependent inhibition using the specific competitive SDH
inhibitor malonate in concentrations ranging from 0 to 500 mM. For this purpose, malonate was added
prior to DCIP addition and the assay was performed as described.
4.13. Seahorse Analysis
Oxygen consumption rate as an indicator for mitochondrial oxidative phosphorylation activity in
PDECs from mono- and co-culture settings was examined with a Seahorse XF Analyzer performing a
XFp Mito Stress Test (both Agilent, Santa Clara, CA, USA) according to the manufacturer’s instructions.
In preparation for the measurement, XFp Extracellular Flux Cassettes were incubated with 200 µL
Calibrant Solution over night at 37 ◦C and XFp Cell Culture Miniplates were coated with 0.01%
poly-D-lysine. Prior to the measurement, 4 × 104 PDECs were washed twice in Mito-Medium,
resuspended in 175 µL Mito-Medium and transferred to the prepared XFp Cell Culture Miniplate.
Afterwards, cells were incubated for 1 h at 37 ◦C, 5% CO2 and 85% relative humidity. Injection ports
of the device were filled with 1 µM oligomycin, 0.5 M FCCP and 0.5 M rotenone + antimycin A,
respectively. Finally, XFp Extracellular Flux Cassette was equilibrated in the Seahorse XF Analyzer, XFp
Cell Culture Minplate was loaded and XFp Mito Stress Test started. Data evaluation was performed
with the Wave Desktop V2.2 software (Agilent, Santa Clara, CA, USA).
4.14. Statistical Analysis
Statistical analyses were performed using SigmaPlot v12.5 provided by Systat (Erkrath, Germany).
First, data were tested for normality and equal variance by Shapiro-Wilk and Equal Variance test,
respectively. For comparison of two-groups comprising parametrically distributed datasets, t-test was
applied. Two groups of datasets which failed normality or equal variance test were analyzed with
Mann-Whitney Rank Sum test. Parametric data of multiple groups were checked with one-way analysis
of variance (one-way ANOVA) for statistical significance. Non-parametrical datasets of multiple groups
were analyzed with Kruskal-Wallis one-way ANOVA on ranks test. Statistically significant differences
between the groups were assumed at p-values < 0.05 according to Student-Newman-Keuls method
(parametric data) and Dunn’s method (non-parametric data), respectively. Statistically significant
differences with p-values < 0.05 were marked with an asterisk (*).
5. Conclusions
Overall, this study provides experimental evidence that upregulation of SDHB expression and
thereby enhanced SDH activity in PDECs under inflammatory conditions can be regarded as a
control mechanism to prevent excessive PDEC cell growth and expansion supporting its role as tumor
suppressor. Accordingly, reduction or loss of SDHB expression due to mutations or stroma alterations
given by accumulation of inflammatory cells and released inflammatory mediators leads to deficient
cell growth control in PDECs and later on PDAC cells thereby contributing to expansion of transformed
cells. Future studies have to unravel in more detail how this altered SDHB expression and activity is
related to an altered flux and usage of metabolites in PDECs. In fact, metabolic reprogramming as
well as SDH inhibition have also been shown to essentially contribute to EMT and with this to the
acquisition of an invasive and cancer stem cell phenotype [47,61] Giving the fact that macrophages
represent a predominant cell population in the stroma of CP and PDAC and are known to promote
EMT and cell invasion of PDECs [13], it can be speculated that they might also impact these processes
via paracrine modulation of SDHB expression. Thus, loss of SDHB expression may promote tumor
development and progression not only via the loss of growth control but also by conferring tumor
initiating and dissemination abilities.
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Abbreviations
The following abbreviations are used in this manuscript.
2-NBDG 2-(N-(7-Nitrobenz-2-oxa-1.3-diazol-4-yl)-Amino)-2-Deoxyglucose
CP Chronic pancreatitis
EMT Epithelial-Mesenchymal-Transition
G6PD Glucose-6-phosphate dehydrogenase
GM-CSF Granulocyte macrophage-colony stimulating factor
HIF-1 Hypoxia-inducible factor-1
LDHA/B Lactate dehydrogenase subunit A/B
OXPHOS Oxidative phosphorylation
PanIN Pancreatic intraepithelial neoplasia
PDAC Pancreatic ductal adenocarcinoma
PDECs Pancreatic ductal epithelial cells
PPP Pentose phosphate pathway
ROS Reactive oxygen species
SDH Succinate dehydrogenase
SDHA/B Succinate dehydrogenase subunit A/B
TCA Tricarboxylic acid
TNF-α Tumor Necrosis Factor-alpha
Appendix A
Figure A1. Elevated basal oxygen consumption rate in H6c7-pBp cells after co-culture with
M1-macrophages. H6c7-pBp cells were mono- or indirectly co-cultured with human M1-macrophages
(coM1) for five days. (A) Representative kinetic of oxygen consumption rate (OCR) by H6c7-pBp cells
from indicated culture settings measured during XFp Mito Stress Test using a Seahorse XF Analyzer.
(B) Basal OCR (= mean OCR before oligomycin injection) by H6c7-pBp cells from indicated culture
conditions. Data are expressed as n-fold change normalized to mono-cultured cells. Data represent
mean +/- SEM of three independent experiments.
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